Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Opus Genetics ( (IRD) ) has provided an announcement.
On June 23, 2025, Opus Genetics announced a funding agreement with the Foundation Fighting Blindness Retinal Degeneration Fund, providing up to $2 million in non-dilutive funding to support the preclinical development of the OPGx-MERTK program. This strategic investment will help advance gene therapies for retinitis pigmentosa caused by MERTK gene mutations, enhancing Opus’ gene therapy pipeline and extending its operational funding into the second half of 2026.
The most recent analyst rating on (IRD) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.
Spark’s Take on IRD Stock
According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.
Opus Genetics faces significant financial challenges, with declining revenues and persistent losses undermining its financial stability. The technical indicators suggest a bearish trend, while the negative corporate event further highlights financing difficulties. These factors contribute to a low overall score, indicating a high-risk investment with uncertain prospects.
To see Spark’s full report on IRD stock, click here.
More about Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene and small molecule therapies for vision-threatening eye diseases. The company’s pipeline includes adeno-associated virus (AAV)-based gene therapies targeting inherited retinal diseases such as Leber congenital amaurosis, bestrophinopathy, and retinitis pigmentosa, with its lead candidate OPGx-LCA5 in a Phase 1/2 trial. Opus is also advancing therapies for diabetic retinopathy and presbyopia.
Average Trading Volume: 908,425
Technical Sentiment Signal: Strong Sell
Current Market Cap: $56.68M
For an in-depth examination of IRD stock, go to TipRanks’ Overview page.